There are 2949 resources available
LBA62 - Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
Presenter: Helena Yu
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1421MO - Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
Presenter: Salah-Eddin Al-Batran
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1422MO - Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
Presenter: Kensei Yamaguchi
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1423MO - End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)
Presenter: Josep Tabernero
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1424MO - Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM
Presenter: Salah-Eddin Al-Batran
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1425MO - Effects of elemental diet for gastrointestinal adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil (EPOC 2 study: JFMC49-1601-C5): A phase III randomized controlled trial
Presenter: Hiroya Takeuchi
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
612MO - Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study
Presenter: Rebeca Lozano Mejorada
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
614MO - Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects
Presenter: Mihaela Aldea
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA22 - Imaging based PCa screening among BRCA mutation carriers: Results from the first round of screening
Presenter: David Margel
Session: Mini Oral - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1080MO - The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition
Presenter: Judith Versluis
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast